Biohaven Ltd.

Biohaven Ltd.

BHVN·NYSE

$11.35

+12%
HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

At a Glance

Live Snapshot
Market Cap$1.20B
EPS-6.8600
P/E Ratio-1.65
Earnings Date08/10/2026

bhvn

Free Cash Flow

Last Annual Value

-610.15M

3-Year CAGR

-22%

5-Year CAGR

-51%

10-Year CAGR

-20%

Biohaven Ltd.

Biohaven Ltd. Competitors Analysis of Free Cash Flow

BHVN · NYSE
CompanyFree Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
BHVN logo
Biohaven Ltd.
NYSE:BHVN
-610.15M
N/AN/AN/A 
-354.66M
N/AN/AN/A
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
-200.60M
N/AN/AN/A
-241.73M
N/AN/AN/A
-66.67M
N/AN/AN/A
-172.35M
N/AN/AN/A
27.93M
N/AN/AN/A
-213.66M
N/AN/AN/A
Biohaven Ltd.

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.35, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

Intrinsic Value
Current Price: $11.35